However, ≃ 40% of patients with HR + /HER2 − breast cancer have mutations in the PIK3CA gene, which can lead to resistance to endocrine-based therapy and eventual disease progression or relapse over time [4–8]. Here, ERBB2 is linked to breast carcinoma.